适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 170
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 64（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
A study to test how BI 764532 is taken up by tumours in people with small-cell lung cancer or neuroendocrine cancereuroendocrine carcinoma (NEC) or small cell carcinoma of any otherorigin, Small cell lung carcinoma (SCLC), Large cells neuroendocrine lung carcinoma (LCNEC)MedDRA version: 21.0Level: LLTClassification code: 10048683Term: Advanced cancer Class: 10029104CTIS2022-501818-54-00Boehringer Ingelheim International GmbH12
进行中（未招募）
1 期
A trial to learn how much budesonide, glycopyrronium, and formoterol fumarate (BGF) gets into and moves throughout the body when it is taken with hydrofluoroolefin (HFO) compared to when it is taken with hydrofluoroalkane (HFA) in healthy adultsot applicable, healthy volunteersCTIS2023-504089-43-00AstraZeneca AB42
进行中（未招募）
1 期
Study to Assess the Effect of Food on the Pharmacokinetics of CA-4948 in Healthy Male SubjectsHematologic malignanciesMedDRA version: 20.0Level: HLTClassification code: 10003817Term: Blood autoimmune disorders Class: 10021428CTIS2023-509691-41-00Curis Inc.14
进行中（未招募）
1 期
A study to test how well different doses of BI 1584862 are tolerated by healthy meHealthy volunteer trialMedDRA version: 20.0Level: SOCClassification code: 10015919Term: Eye disorders Class: 9CTIS2023-503541-54-00Boehringer Ingelheim International GmbH50
招募中
1 期
A study in healthy subjects investigating the safety, tolerability and concentrations of FE 999301 after single and multiple dosesInflammatory Gastrointestinal DiseaseMedDRA version: 20.0Level: HLGTClassification code: 10017969Term: Gastrointestinal inflammatory conditions Class: 10017947CTIS2023-507882-24-00Ferring Pharmaceuticals A/S48